Syfovre was approved for GA in the US last year ... Neuraxpharm and partner Minoryx Therapeutics, meanwhile, were unable to convince the CHMP that they should get conditional approval for PPAR ...

Four months after Europe's Committee for Medicinal Products for Human Use (CHMP) rejected Apellis’ GA application for Syfovre for a second time, Astellas has withdrawn its application for the approval ...

While Syfovre’s revenue miss is no doubt disappointing, the drug remained the market leader in GA with more than 88,500 doses delivered to physicians in the third quarter, Apellis said in its ...

a large Medicare Advantage plan will make SYFOVRE the only preferred product on its formulary. Received a negative opinion from the Committee for Medicinal Products for Human Use (CHMP ...

Apellis Pharmaceuticals (APLS) stock falls as company's Q3 2024 financials disappoint with lower-than-expected U.S. sales ...

The company’s drug, Syfovre, experienced a slight decline in sales for Q3, primarily due to increased gross-to-net adjustments that affected revenue, despite a 7% increase in commercial vial ...

Importantly, we continue to believe SYFOVRE remains on track to becoming a blockbuster drug. Quickly touching on Europe. We were disappointed with the negative CHMP opinion despite multiple ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended that the PD-1 inhibitor be used in combination with platinum- and fluoropyrimidine-based chemotherapy to treat adults with ...

Generated $196.8 million in 3Q 2024 revenues, including $176.6 million in U.S. net product salesGrew SYFOVRE® (pegcetacoplan injection) demand by ...

Apellis Pharmaceuticals Inc (APLS) reports significant revenue growth but faces market and regulatory hurdles in Q3 2024.